ED MATHERS

Ed Mathers stands as a prominent figure in the venture capital landscape, particularly within the dynamic healthcare and biotechnology sectors. As a General Partner at New Enterprise Associates (NEA), one of the world's largest and most active venture capital firms, Mathers plays a pivotal role in shaping the future of medicine and patient care through strategic investments.

At NEA, Ed Mathers is a cornerstone of the firm's robust healthcare practice. His responsibilities encompass identifying promising early to late-stage companies, leading investment rounds, and actively supporting portfolio companies in their growth and development. He brings a unique blend of scientific understanding, operational expertise, and investment acumen to the table, making him a highly sought-after partner for entrepreneurs in the life sciences.

Mathers' investment focus is sharply honed on groundbreaking innovations within healthcare. He primarily targets companies in biotechnology, pharmaceuticals, medical devices, and diagnostics. His portfolio often includes firms developing novel therapeutics for unmet medical needs, advanced diagnostic tools, and disruptive medical technologies designed to improve patient outcomes and healthcare efficiency. He is known for backing companies with strong scientific foundations, visionary leadership, and significant market potential.

Before joining NEA, Ed Mathers built an impressive career marked by significant operational leadership roles in the pharmaceutical and biotechnology industries. Most notably, he was a co-founder and Executive Vice President of Commercial Operations at MedImmune, Inc., a leading biotechnology company that was later acquired by AstraZeneca. During his tenure at MedImmune, he was instrumental in building the company's commercial infrastructure and bringing several key products to market. His extensive experience also includes leadership positions at companies such as Innovex, a Quintiles company, and Glaxo Wellcome (now GlaxoSmithKline). This deep operational background provides him with invaluable insights into the challenges and opportunities faced by biotech and pharma companies, allowing him to provide strategic guidance that extends far beyond capital investment.

Among his notable investments, Ed Mathers has supported a diverse range of companies that have gone on to achieve significant milestones. These include Amicus Therapeutics (NASDAQ: FOLD), a global biotechnology company focused on rare diseases; Lumos Pharma (NASDAQ: LUMO), developing treatments for rare endocrine disorders; and Precision Biosciences (NASDAQ: DTIL), a genome editing company. His involvement often extends to serving on the boards of these companies, providing strategic oversight and leveraging his vast network to foster success.

Ed Mathers' enduring impact on the healthcare investment landscape is a testament to his strategic vision, deep industry knowledge, and unwavering commitment to fostering innovation that addresses critical health challenges worldwide. His work at NEA continues to drive advancements in biotechnology and medical science, ultimately benefiting patients globally.